1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEMMADCat. No.: HY-15581CAS No.: 203849-91-6Synonyms: Demethyldolastatin 10; Monomethylauristatin D; MonomethylDolastatin 10分式: CHNOS分量: 771.06作靶點: Microtubule/Tubulin; ADC Cytotoxin作通路: Cell Cycle/DNA Damage; Cytoskeleton; Antibo

2、dy-drugConjugate/ADC Related儲存式: 4C, stored under nitrogen* In solvent : -80C, 6 months; -20C, 1 month (stored undernitrogen)溶解性數據體外實驗 DMSO : 24.5 mg/mL (31.77 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.2969 mL 6.4846 mL 12.9692 mL5 mM 0.2594 mL 1.2969 mL 2.

3、5938 mL10 mM 0.1297 mL 0.6485 mL 1.2969 mL請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 MMAD種有效的微管 (tubulin) 抑制劑， 抗體藥物偶聯物 (ADCs) 中的活性分。IC50 & Target Tubulin 1體外研究MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous a

4、ntibody-drug conjugates (ADCs) with a drug-to-antibody ratio of 2.0. The resulting conjugates1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEdemonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells.When compared with ADCs prepared by cysteine alkyla

5、tion following native interchain disulfide reduction,site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity 1.體內研究 The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. Theyalso have an improved toxicology profile in rats 1.REFERENCES1. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-37